Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Ws Bimatoprost (exclusively In The Effective Strength 0.1 Mg/ml), Atc S01ee03 F. D. Z. 01.6.26-31.5.28 (plus V. Option 1x12 Months) 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement For The Active Ingredient Pomalidomide For The Period From June 1, 2026, To May 31, 2028, With An Additional Option For 12 Months. Pomalidomide 1mg, Pomalidomide 2mg, Package 14st 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Clobazam For The Period From 01.06.2026 To 31.05.2028 (plus An Option For 1x12 Months). Clobazam 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Clobazam (excl. Dafo Sue), Atc N05ba09 For The Period June 1st, 2026 - May 31st, 2028 (plus V. Option 1x12 Months) 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Teduglutide, Atc A16ax08 For The Period June 1st, 2026 - May 31st, 2028 (plus Extension Option 1x12 Months) 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Piperacillin + Tazobactam, Atc J01cr05 For The Period June 1st, 2026 - May 31st, 2028 (plus V. Option 1x12 Months) 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Tianeptine, Atc N06ax14 For The Period June 1st, 2026 - May 31st, 2028 (plus Extension Option 1x12 Months) 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Teduglutide, Atc A16ax08 For The Period 01.06.2026 To 31.05.2028 (plus Extension Option 1x12 Months) 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Clobazam (excluding Dafo Tab), Atc N05ba09 For The Period 01.06.2026 To 31.05.2028 (plus Option For 1x12 Months) 2029-04-05
Germany The Dak-gesundheit Intends To Conclude A Non-exclusive Discount Agreement Under § 130a Abs. 8 Sgb V For The Active Ingredient Mesalazine (excluding Dafo Rsu + Kli), Atc A07ec02 For The Period From 01.06.2026 To 31.05.2028, With An Option To Extend For 1x1 2029-04-05
Whats app